THTX
TheratechnologiesTHTX
THTX
About: Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
Employees: 105
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
39% more capital invested
Capital invested by funds: $18.1M [Q3] → $25.1M (+$7.01M) [Q4]
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
11% more funds holding
Funds holding: 37 [Q3] → 41 (+4) [Q4]
1.49% less ownership
Funds ownership: 31.72% [Q3] → 30.23% (-1.49%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for THTX.
Financial journalist opinion
Based on 8 articles about THTX published over the past 30 days
Negative
Seeking Alpha
1 week ago
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV, faces competition and supply issues, with uncertain prospects for its new formulation and other niche products. Theratechnologies' financials are dire, with only $4.6 million in cash and a high burn rate, necessitating urgent external financing or a strategic transaction.
Neutral
GlobeNewsWire
1 week ago
Theratechnologies Provides Update on Sale Process
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized the special committee, consisting of independent and disinterested directors (the “Special Committee”), to oversee the process and make a recommendation to the full Board. To support this process, in addition to Barclays as financial advisor and Fasken as legal advisor, the Special Committee has also engaged Raymond James as independent financial advisor and Norton Rose Fulbright as independent legal advisor.
Neutral
Business Wire
1 week ago
Soleus Capital Issues Letter to The Board of Theratechnologies
GREENWICH, Conn.--(BUSINESS WIRE)--Soleus Capital Management, L.P. (“Soleus Capital”), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (the “Company”), today sent a letter to the Board of Directors of the Company. In its letter, Soleus Capital described its belief that an acquisition of the Company is in the best interest of the Company's shareholders and urged the Board to pursue an acquisition offer announced earlier today by Futu.
Neutral
GlobeNewsWire
1 week ago
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press release issued today by Future Pak, LLC (“Future Pak”) regarding its proposals to acquire the Company.
Neutral
Business Wire
2 weeks ago
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. (“Theratechnologies”) (NASDAQ: THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51 to $4.50 per share. The proposal represents a total enterprise value of up to $255 million, comprisin.
Neutral
Seeking Alpha
2 weeks ago
Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2025 Earnings Conference Call April 9, 2025 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer John Leasure - Global Commercial Officer Conference Call Participants Andre Uddin - Research Capital Justin Walsh - Jones Trading Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter 2025 Earnings Call.
Neutral
GlobeNewsWire
2 weeks ago
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the first quarter 2025, ended February 28, 2025. All figures are in U.S. dollars unless otherwise stated.
Neutral
GlobeNewsWire
3 weeks ago
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET.
Neutral
GlobeNewsWire
1 month ago
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The Company will commercialize the new formulation under the tradename EGRIFTA WR™.
Neutral
GlobeNewsWire
1 month ago
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
Charts implemented using Lightweight Charts™